URA (GEMR) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
28 Sep, 2026Executive summary
2025 marked a year of transition, recapitalisation, and governance improvements, with a focus on strengthening the balance sheet and reassessing the asset portfolio.
Operational progress included initial test sales of emeralds from the Gravelotte project and early-stage development at Curlew in Australia.
A significant recapitalisation was completed, including a £617k equity subscription, £1.5m convertible loan note, and planned conversion of £230k in accrued fees to equity.
The company adopted a Cryptocurrency and Digital Asset Treasury Policy and made its first Bitcoin allocation post year-end.
Financial highlights
First revenues of $57k (£45k) from trial emerald sales at Gravelotte; other projects remain pre-revenue.
Group loss reduced to £0.9m (2024: £1.9m restated); company loss £0.7m (2024: £1.4m restated), mainly due to non-recurrence of prior year impairment.
Group cash at year-end: £1.61m (2024: £414k); company cash: £129k (2024: £283k).
Net cash outflow from operations: £781k (2024: £550k); net increase in cash: £1.25m (2024: £256k decrease).
Total liabilities increased to £1.81m (2024: £489k), mainly from convertible loan notes.
Outlook and guidance
Entering 2026 with improved capital base, refreshed leadership, and broader strategic toolkit.
Board progressing corporate, financing, and strategic initiatives to enhance financial strength and flexibility.
Ongoing focus on advancing Gravelotte to full-scale production and unlocking value from other assets.
Latest events from URA
- Losses widened and liabilities were converted to equity as the group targets gold processing expansion.GEMR
H1 2026 - Operational milestones, recapitalisation, and strategic initiatives set the stage for future growth.GEMR
H1 2025 - Emerald production launched at Gravelotte, positioning URA for growth and first revenues.GEMR
H1 2024 - £1.96m loss in 2024; first emerald sales post-period, but funding and going concern risks persist.GEMR
H2 2024